Periactin was not taken off the market for safety or effectiveness concerns. The FDA formally determined in 2003 that the brand-name Periactin (cyproheptadine hydrochloride) 4-mg tablets were discontinued for business reasons, not because the drug was dangerous or didn’t work. The active ingredient, cyproheptadine, remains available by prescription in generic form in the United States.
This is a common pattern in the pharmaceutical industry: a brand name disappears from pharmacy shelves, and people reasonably assume something went wrong. In Periactin’s case, the manufacturer simply stopped marketing the branded product, likely because generic competition made it unprofitable. The FDA lists Periactin in the “Discontinued Drug Product List” section of its Orange Book, a category specifically reserved for drugs pulled for reasons other than safety or effectiveness.
What Periactin Is and What It Treats
Cyproheptadine, the drug sold as Periactin, is a first-generation antihistamine. It blocks both histamine and serotonin in the body. Its FDA-approved use is for allergy symptoms, and it was historically considered a go-to medication for a specific type of hives triggered by cold exposure.
Beyond allergies, cyproheptadine is widely known for a notable side effect: increased appetite and weight gain. This led to extensive off-label use as an appetite stimulant, particularly in underweight patients, children with poor appetite, and people recovering from illness. That appetite-boosting reputation has kept the drug relevant long after the brand name disappeared.
Why the Brand Name Disappeared
When a drug’s patent expires, generic manufacturers can produce the same medication at a fraction of the cost. For older, inexpensive drugs like cyproheptadine, the brand-name version often can’t compete on price. The original manufacturer has little financial incentive to keep marketing, packaging, and distributing a branded product that pharmacies and insurers will substitute with a cheaper generic anyway.
This is exactly what happened with Periactin. The manufacturer voluntarily withdrew the brand from the market. The FDA investigated and confirmed in a 2003 Federal Register notice that the withdrawal had nothing to do with safety signals, adverse event patterns, or questions about whether the drug actually worked. Generic cyproheptadine tablets continued to be prescribed and dispensed without interruption.
Side Effects Worth Knowing About
While Periactin wasn’t pulled for safety reasons, cyproheptadine does carry real side effects, particularly because it’s a first-generation antihistamine with strong sedating and anticholinergic properties. The most common effects are drowsiness and sleepiness, which are often transient but can impair driving and concentration. Other frequently reported side effects include dizziness, dry mouth, disturbed coordination, and confusion.
The drug poses particular risks at both ends of the age spectrum. In young children, antihistamines like cyproheptadine can sometimes cause the opposite of sedation, producing excitation, restlessness, and irritability. In overdose situations, especially in infants and young children, the consequences can be severe: hallucinations, seizures, respiratory failure, and in extreme cases, death. The drug should never be given to newborns or premature infants.
For older adults, cyproheptadine is generally not recommended. It’s more likely to cause dizziness, excessive sedation, and drops in blood pressure in people over 65. MedlinePlus, the National Library of Medicine’s consumer resource, notes that older adults should typically use safer alternatives.
The Apetamin Problem
Cyproheptadine’s appetite-stimulating effects have created a separate, more troubling market issue. A product called Apetamin, which contains cyproheptadine, has been sold illegally online and in some retail stores as a weight gain and body-shaping supplement. The FDA has explicitly warned consumers that Apetamin is potentially dangerous and has never been reviewed for safety or effectiveness in the U.S.
Because Apetamin is unregulated, people using it have no medical guidance on dosing. The FDA reviewed adverse event reports involving young adults taking Apetamin and found cases of nervous system problems (dizziness, excessive sleepiness, tremor), irregular heartbeat, and liver injury. One published case described a person who developed autoimmune hepatitis after just six weeks of daily use, a chronic condition that can progress to liver failure if untreated. Antihistamine overdose from products like these can cause disorientation, hallucinations, seizures, dangerously slow breathing and heart rate, coma, and death within six hours.
This is an important distinction: the prescription generic version of cyproheptadine, used under medical supervision, remains a legitimate medication. The danger lies in unregulated products containing the same active ingredient, sold without dosing guidance or safety monitoring.
Why Doctors Prescribe It Less Often Now
Even though generic cyproheptadine is still available, it’s prescribed less frequently for allergies than it once was. The reason is straightforward: newer antihistamines work just as well without the heavy sedation.
Second-generation antihistamines like cetirizine, loratadine, fexofenadine, and levocetirizine all block the same histamine receptors responsible for allergy symptoms. Loratadine, for example, causes sedation at rates not significantly different from a placebo. These newer options also offer convenient once-daily dosing, compared to cyproheptadine’s two or three doses per day. For most people with allergies or hives, a second-generation antihistamine is simply a better experience: fewer side effects, less drowsiness, and less impact on daily life.
Cyproheptadine still has a niche. Its serotonin-blocking properties make it useful in certain clinical situations that newer antihistamines don’t address, and its appetite-stimulating side effect remains valuable for specific patients who need to gain weight. But for routine allergy treatment, it has largely been replaced.